Tagdolutegravir

Updated guidelines for PEP (Post-Exposure Prophylaxis) after non-occupational and occupational exposure to HIV 

U

Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), June 2023 ASHM has updated the National Guidelines for Post-Exposure Prophylaxis (PEP) after non-occupational and occupational exposure to HIV .  These guidelines outline the updated Australian recommendations for human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) following potential or known exposure...

Support for ending and managing HIV

S

Australian Government Department of Health, 29 November 2018 The Australian Government is strengthening its commitment to ending HIV with the announcement of funding for a new strategy that aims to virtually eliminate the transmission of HIV, the approval of the first HIV self-testing kit and the listing of a new medicine on the PBS. The first HIV self-testing kit, the Atomo Self Test was...

New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

N

European Medicines Agency, 18/05/2018 The European Medicines Agency (EMA) is evaluating preliminary results from a study which found 4 cases of birth defects such as spina bifida (malformed spinal cord) in babies born to mothers who became pregnant while taking dolutegravir. While EMA is assessing the new evidence it has issued the following precautionary advice: Dolutegravir HIV medicines should...

Your sidebar area is currently empty. Hurry up and add some widgets.